Virtus Biotech ETF
BBP
7 hedge funds and large institutions have $1.02M invested in Virtus Biotech ETF in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
250% more funds holding
Funds holding: 2 → 7 (+5)
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
48% less capital invested
Capital invested by funds: $1.96M → $1.02M (-$938K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$444K |
| 2 |
LPL Financial
San Diego,
California
|
+$397K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$58.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$34.5K |
| 5 |
FWM
Focused Wealth Management
Newburgh,
New York
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.96M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
BBP Hedge Fund Activity: Q1 2015 in Review
7 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q1 2015, worth a combined $1.02M — down 48% from $1.96M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BBP positions and 2 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $444K. The largest seller was Deutsche Bank, exiting entirely with an estimated $1.96M sold.
- 7 institutional investors held Virtus Biotech ETF (BBP) as of Q1 2015, up from 2 in Q4 2014.
- Funds reported $1.02M of Virtus Biotech ETF stock for Q1 2015, down 48% quarter-over-quarter.
- 7 funds opened new Virtus Biotech ETF positions in Q1 2015 and 2 closed out, a net change of +5 holders.
- The largest Virtus Biotech ETF buyer in Q1 2015 was Credit Suisse, an estimated $444K added.
- The largest Virtus Biotech ETF seller in Q1 2015 was Deutsche Bank, an estimated $1.96M sold.
Based on aggregated 13F filings for Q1 2015.